The groundbreaking rise of Viagra has long been a benchmark of pharmaceutical success, yet its legacy within the broader sector now presents questions about future returns . Copycat versions are diminishing patent protection , leading to worries that supporting companies heavily reliant to Viagra's former position could be a dangerous decision , es